To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2

NCT05895110 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: Recombinant Novel Coronavirus vaccine (CHO Cells)

Sponsor

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.